Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/1/2024 | $119.00 → $129.00 | Buy | Needham |
| 5/22/2023 | $140.00 | Buy | CL King |
| 3/27/2023 | $124.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/21/2023 | $96.00 | Equal Weight | Wells Fargo |
| 10/12/2022 | $85.00 | Hold | Jefferies |
| 3/2/2022 | $155.00 | Neutral | BofA Securities |
| 1/21/2022 | $158.00 → $150.00 | Buy | Needham |
| 10/28/2021 | $150.00 → $158.00 | Buy | Needham |
CONMED Corporation (NYSE:CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat J. Beyer, Chief Operating Officer, will participate in a fireside chat at the Piper Sandler Healthcare Conference at 12:30 p.m. ET on Tuesday, December 3, 2024. A live video webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.conmed.com and will be available for replay following the event. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used
CONMED Corporation (NYSE:CNMD) today announced that it will participate in fireside chats at the following two investor conferences in November: Conference: Stifel Healthcare Conference Location: New York, NY Date: Tuesday, November 19, 2024 Presentation: 8:35 a.m. ET Speakers: Curt R. Hartman, President and Chief Executive Officer, and Nate Miersma, Vice President and General Manager, U.S. Orthopedics Conference: Jefferies London Healthcare Conference Location: London, UK Date: Wednesday, November 20, 2024 Presentation: 11:00 a.m. GMT (6:00 a.m. ET) Speakers: Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat J. Beyer, Chief Operating Officer A live webcast of
CONMED Corporation (NYSE:CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Sales of $316.7 million increased 4.0% year-over-year as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57 compared to diluted net earnings per share (GAAP) of $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share(1) were $1.05, an increase of 16.7% compared to the third quarter of 2023. Announced COO Patrick Beyer to succeed Curt Hartman as President and CEO effective January 1, 2025, upon Mr. Hartman's retirement. "Our third quarter results were largely in line with our expecta
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $107 to $106.
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) with a Buy and maintains $107 price target.
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. CONMED The Trade: CONMED Corporation (NYSE:CNMD) Chief Operating Officer Pat Beyer acquired a total of 3,000 shares at an
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
10-Q - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
CONMED Corporation (NYSE:CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Sales of $316.7 million increased 4.0% year-over-year as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57 compared to diluted net earnings per share (GAAP) of $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share(1) were $1.05, an increase of 16.7% compared to the third quarter of 2023. Announced COO Patrick Beyer to succeed Curt Hartman as President and CEO effective January 1, 2025, upon Mr. Hartman's retirement. "Our third quarter results were largely in line with our expecta
As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE:CNMD) announced preliminary financial information for the third quarter of 2024. The Company expects revenue in the range of $315 million to $318 million and adjusted diluted net earnings per share growth in excess of its previously provided guidance of 9% to 11%. CONMED will report full financial results for the third quarter of 2024 after the market close on Wednesday, October 30, 2024. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-r
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 8, 2024, payable on October 4, 2024, to all shareholders of record as of September 16, 2024. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am
Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously
CL King initiated coverage of CONMED with a rating of Buy and set a new price target of $140.00
KeyBanc Capital Markets upgraded CONMED from Sector Weight to Overweight and set a new price target of $124.00